Features
A Roundtable on Complications in Retinal Surgery
Surgeons discuss cases where the unexpected happened and how they managed them.
By Christina Y. Weng, MD, MBA, Lejla Vajzovic, MD, FASRS, Yoshihiro Yonekawa, MD, et al.
Tips for Managing Complicated Macular Holes
Mastering several techniques enables retina specialists to offer tailored approaches to patients.
By Dilraj S. Grewal, MD, FASRS
Combined Phacovitrectomy Surgery
Update on outcomes, innovations, and interspecialty collaborations.
By Hiram J. Jimenez Davila, MD, Victor M. Villegas, MD, Timothy G. Murray, MD, MBA, FACS
Management of Dislocated Intraocular Lenses
Many options exist that retina surgeons can use for repositioning and exchange.
By Maria H. Berrocal, MD, Luis A. Acaba-Berrocal, MD
Web Exclusives
Clinical Implications of Associations Between Diabetic Retinopathy and Age-related Macular Degeneration
An understanding of the current literature can inform patient counseling.
By Deborah Li, BA, Nicholas Fazio, BS, Michael Wolek, MD, et al.
Supported Content
36-month Data from the CALM Registry in Uveitis Treatment
An overview of first-time data assessing fluocinolone acetonide intravitreal implant outcomes in posterior segment chronic non-infectious uveitis
By Michael A. Singer, MD
RHONE-X Highlights DME Disease Control and Durability with Faricimab
By Arshad M. Khanani, MD, MA, FASRS, Michael A. Singer, MD
Departments
Upfront: Same Retinal Physician, New Platform
As media evolves, so do our trusted sources of clinical information.
By Peter K. Kaiser, MD
Coding: Understanding the New +G2211 Code
Retina specialists must be careful when billing this new HCPCS code, as it will only be appropriate in rare cases.
By Brandy H. Sperry, COMT, COE, CPC, CPMA
Uveitis Corner: A 2024 Update on Clinical Trials in Uveitis
This review will focus on the phase 2-4 uveitis trials listed as “active” on clinicaltrials.gov, with the majority assessing noninfectious uveitis.
By Sruthi Arepalli, MD
New Product Applications: C. Light Launches First-of-Its-Kind Retitrack
Monitoring eye movement can provide new insights.
By Karen Appold, contributing writer
Clinical Trial Update July/August 2024
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
News
Phase 2 PRISM Trial Data on 4D-150 Gene Therapy Presented at 2024 ASRS Meeting
Patients showed a durable improvement of vision with 93% remaining injection free.
By Jennifer Ford, senior managing editor
Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS
Two-thirds of eyes remained supplement free.
By Jennifer Ford, senior managing editor
Outcomes of Faricimab in DME Study Presented at ASRS
Data from the RHONE-X extension trial, presented for the first time at the meeting, show that Vabysmo maintained safety and efficacy over 4 years.
TEASE-3 Study Data on Oral Therapy for Stargardt Disease Presented at ASRS
Younger, asymptomatic siblings of Stargardt patients maintained vision.
By Jennifer Ford, senior managing editor
Interim Phase 1 HELIOS Trial Data of Axpaxli for NPDR Presented at ASRS
The axitinib implant demonstrated both safety and efficacy.
By Jennifer Ford, senior managing editor
Top-line Data on RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa Presented at ASRS
Thirty percent of patients maintained 3-line vision gain.
By Jennifer Ford, senior managing editor
FDA Clears AI Device for Portable Diabetic Retinopathy Screening
AEYE Health announced that it has received the first FDA clearance for a fully autonomous AI system that diagnoses referable diabetic retinopathy (DR) from retinal images captured by a handheld camera.
By Rochelle Nataloni, contributing writer
Foundation Fighting Blindness Partners With PreventionGenetics
The My Retina Tracker Genetic Testing Program aims to advance research focused on inherited retinal diseases.
By Rochelle Nataloni, contributing writer
First Patient Dosed in Inflammasome GA Clinical Trial
The trial will study kamuvudine-8 for geographic atrophy due to age-related macular degeneration.
By Rochelle Nataloni, contributing writer
Ocugen Meets Dosing Milestone in Stargardt Disease Trial
Dosing is complete in a phase 1/2 trial for a modifier gene therapy for Stargardt disease.
By Rochelle Nataloni, contributing writer
Blue-light IOLs Reduce Progression of Macular Atrophy, But Not Incidence
A recent study published in the American Journal of Ophthalmology evaluated the impact of blue-light intraocular lenses.
By Rochelle Nataloni, contributing writer
CRISPR Trial Demonstrates Potential Advances for Inherited Blindness
Results showed 11 of 14 patients had improvement in vision and quality-of-life measures.
By Rochelle Nataloni, contributing writer
Ocular Telehealth Program Enables Remote Retina Disease Screening
Visionix and 20/20NOW announced the launch of their collaborative Ocular Telehealth Program.
By Rochelle Nataloni, contributing writer
FDA Grants De Novo Status to Notal’s Patient-operated OCT Device
Retina specialists will be able to prescribe the Scanly Home OCT device for home monitoring.
New Algorithm to Identify Patients With UME Presented at ARVO
The algorithm identified 3 times more patients with active UME compared to only using ICD-10 codes.
By Rochelle Nataloni, contributing writer
Eye2Gene and Heidelberg Announce Collaborative Partnership
The collaboration aims to provide eye care professionals with insights into genetic diagnosis of inherited retinal disease.
By Rochelle Nataloni, contributing writer
PULSAR Analysis of Aflibercept in nAMD Presented at ARVO
Findings suggest that aflibercept 8 mg with extended dosing intervals is as effective as the more frequent 2 mg dosing.
By Rochelle Nataloni, contributing writer
Study Highlights Demographic Disparities in Diabetic Retinopathy Care
The study assessed associations between neighborhood-level social determinants of health and risk for lapses in diabetic retinopathy care.
By Rochelle Nataloni, contributing writer
Initial UK Faricimab Real-world Outcomes Presented at ARVO
Results suggest a rapid extension in faricimab treatment intervals after the initial doses.
By Rochelle Nataloni, contributing writer
Study: Time to First Anti-VEGF Injection in Treatment-naïve Wet AMD Patients
Patients who wait to start treatment might have worse outcomes.
By Rochelle Nataloni, contributing writer
New ARCHER ANX007 in GA Treatment Findings Presented at ARVO
David Boyer, MD, presented results highlighting a neuroprotective mechanism.
By Rochelle Nataloni, contributing writer
Understanding Risk Factors for Posterior Capsular Rupture
Austrian study finds that history of intravitreal injections does not increase the likelihood of PCR during cataract surgery.
Alcon’s Unity VCS and CS Receive FDA 510(k) Clearance
The company's new systems are the first solutions to be introduced from Alcon’s Unity portfolio of surgical equipment.
ANI Pharmaceuticals to Acquire Alimera Sciences
The $381 million deal expands ANI’s presence in ophthalmology.
Optogenetic Therapy Shows Promise for Retinitis Pigmentosa
Results of the RESTORE trial indicate that MCO-010 optogenetic therapy significantly improves visual acuity in patients with retinitis pigmentosa.
New Analysis Published of ROMEO Study of Omni Surgical System
Omni proves effective in lowering IOP and reducing medications in all stages of glaucoma.
FDA Approves Anti-VEGF Biosimilar Drug
Formycon AG’s Ahzantive becomes the third aflibercept biosimilar approved for use in the United States.
Skye Bioscience Halts Eye Disease Drug Development After Glaucoma Study Disappointment
SBI-100 failed to reduce eye pressure in a mid-stage study on primary open-angle glaucoma patients.
Vabysmo Prefilled Syringe Receives FDA Approval
Genentech’s Vabysmo PFS will become available to US retina specialists and their patients in the coming months.
Eversight Announces Collaboration with LighTopTech
The 4-year partnership aims to improve imaging modalities for eye tissues by utilizing OCX imaging technology.
Merck Acquires EyeBio
The deal, valued at up to $3 billion, expands Merck’s ophthalmology pipeline.
APX3330 Shows Promise in Slowing DR Progression
A phase 2 trial of the drug demonstrates potential to delay or prevent progression of diabetic retinopathy.
Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
Phase 3 trials demonstrate faricimab’s potential to extend treatment intervals up to 16 weeks while maintaining visual gains in patients with diabetic macular edema.
27-gauge Vitrectomy Shows Comparable Outcomes to 25-gauge in Trial
The vitrectomy systems had similar surgical times and complication rates, with 27-gauge allowing more sutureless surgeries.
Cardiovascular Health Linked to Lower Retinopathy Risk in US Adults
Analysis of national data shows moderate to high cardiovascular health scores are associated with reduced odds of diabetic or hypertensive retinopathy.
Sickle Cell Drug Shows Promise in Stabilizing Vision in Rare Genetic Disease
Crizanlizumab shows promise in stabilizing vision and potentially modifying disease progression in patients with the rare genetic disorder RVCL-S.
Supplements Slow Geographic Atrophy Progression
New analysis shows benefit to taking AREDS2 formula vitamins during the late stage of dry age-related macular degeneration.
Two-year Data on Susvimo Reported at ASRS
Phase 3 data presented at ASRS show the ocular implant’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.
Phase 2 LUNA Trial Data Presented at ASRS
A single injection of the gene therapy Ixo-vec reduced anti-VEGF injection burden by 90% to 95% in wet AMD patients.
Ellipsoid Zone Integrity at Baseline Predicts Geographic Atrophy Progression Rate
Analysis of data from the GATHER trials found eyes with greater ellipsoid zone attenuation and larger EZ-GA gap showed faster GA growth over 12 months.